StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Saturday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.19 on Friday. Oragenics has a 1 year low of $0.18 and a 1 year high of $3.43. The stock has a market capitalization of $4.02 million, a PE ratio of -0.03 and a beta of 0.87. The business’s 50-day moving average is $0.27 and its 200 day moving average is $0.32.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.